Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.
Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Vasc Med. 2023 Oct;28(5):443-448. doi: 10.1177/1358863X231189758. Epub 2023 Aug 9.
Underweight patients may be at an increased risk of bleeding while receiving venous thromboembolism (VTE) prophylaxis. Additional evidence is needed to identify patient-specific factors associated with bleeding. The objective of the study was to describe the incidence and identify risk factors associated with bleeding in low-weight (⩽ 60 kg) adult patients receiving subcutaneous unfractionated heparin (SQH) for VTE prophylaxis.
This was a single-center, retrospective, nested case-control study of low-weight patients receiving SQH for VTE prophylaxis for ⩾ 48 hours. Cases, patients with clinically relevant bleeding while receiving SQH, and controls, patients without a bleeding event, were matched in a 1:3 ratio for age, sex, primary service (surgical or medical), and time at risk of bleeding on SQH to determine factors associated with bleeding.
A total of 3761 patients met the inclusion criteria, of which 38 cases of clinically relevant bleeding were identified. The bleeding incidence was 1% at hospital day 6 and 2.8% at hospital day 14. Most patients in this study (69%) received SQH 5000 units three times daily. ICU admission at SQH start was associated with bleeding, OR 2.97 (95% CI 1.21-7.29).
Bleeding in low-weight patients on prophylactic SQH was uncommon. Patients admitted to the ICU at time of SQH start may be at a higher risk of bleeding. Further studies are needed to detect additional risk factors associated with bleeding and investigate the effects of reduced dosing in this population.
接受静脉血栓栓塞症(VTE)预防治疗的体重不足患者可能有更高的出血风险。需要更多的证据来确定与出血相关的患者特定因素。本研究的目的是描述低体重(≤60kg)成年患者接受皮下普通肝素(SQH)预防 VTE 治疗时出血的发生率,并确定与出血相关的危险因素。
这是一项单中心、回顾性、嵌套病例对照研究,纳入了接受 SQH 预防 VTE 治疗≥48 小时的低体重患者。病例组为接受 SQH 治疗时发生临床相关出血的患者,对照组为无出血事件的患者,按照年龄、性别、主要科室(外科或内科)和 SQH 出血风险时间进行 1:3 匹配,以确定与出血相关的因素。
共有 3761 名患者符合纳入标准,其中 38 例发生临床相关出血。出血发生率在住院第 6 天为 1%,在住院第 14 天为 2.8%。本研究中大多数患者(69%)接受每日三次 5000 单位 SQH。SQH 开始时入住 ICU 与出血相关,OR 2.97(95%CI 1.21-7.29)。
接受预防性 SQH 治疗的低体重患者出血并不常见。在 SQH 开始时入住 ICU 的患者可能有更高的出血风险。需要进一步研究以发现与出血相关的其他危险因素,并研究该人群中减少剂量的效果。